KALA Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Kala Bio Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerKALA

Market Cap41.5M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

Kala Bio Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for rK28 in Visceral Leishmaniasis.

Pipeline

Asset	Indication	Modality	Stage	Public Note
rK28	Visceral Leishmaniasis	n/a	n/a	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT05386875	n/a	UNKNOWN	625	2023-12-31

Scientific Context

literature_publication | Fuchs' Endothelial Corneal Dystrophy and Cardiometabolic Comorbidities.
literature_publication | Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
literature_publication | Association Between Self-Reported Smoking Behaviour and Fuchs Endothelial Corneal Dystrophy: A Cross-Sectional Analysis.
literature_publication | Lotilaner ophthalmic solution 0.25% in the treatment of Demodex blepharitis: A case report.
literature_publication | Malignancy Risk after Ophthalmic Herpes Infection within a Diverse United States Cohort.

Want the full KALA research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.